Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Operating Leases (2022 - 2025)

Amylyx Pharmaceuticals has reported Operating Leases over the past 4 years, most recently at $4.7 million for Q4 2025.

  • Quarterly results put Operating Leases at $4.7 million for Q4 2025, up 914.69% from a year ago — trailing twelve months through Dec 2025 was $4.7 million (up 914.69% YoY), and the annual figure for FY2025 was $4.7 million, up 914.69%.
  • Operating Leases for Q4 2025 was $4.7 million at Amylyx Pharmaceuticals, down from $5.0 million in the prior quarter.
  • Over the last five years, Operating Leases for AMLX hit a ceiling of $5.8 million in Q1 2022 and a floor of $327000.0 in Q1 2025.
  • Median Operating Leases over the past 4 years was $4.0 million (2022), compared with a mean of $3.4 million.
  • Biggest five-year swings in Operating Leases: plummeted 76.62% in 2024 and later soared 914.69% in 2025.
  • Amylyx Pharmaceuticals' Operating Leases stood at $4.2 million in 2022, then plummeted by 53.27% to $2.0 million in 2023, then crashed by 76.62% to $463000.0 in 2024, then soared by 914.69% to $4.7 million in 2025.
  • The last three reported values for Operating Leases were $4.7 million (Q4 2025), $5.0 million (Q3 2025), and $5.3 million (Q2 2025) per Business Quant data.